Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

89.48 +0.49 (+0.55%)
Streaming Delayed Price Updated: 11:27 AM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
News headline image
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre ↗
Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe." 
Via Benzinga
News headline image
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗
Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines. 
Via Benzinga
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
News headline image
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease ↗
Via Stocktwits
Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years ↗
Via Stocktwits
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Is the Market Bullish or Bearish on AstraZeneca? ↗
 
Via Benzinga
News headline image
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial ↗
AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles. 
Via Benzinga
Advancing Cancer Research Brings New Hope for Patients Worldwide
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
From AstraZeneca
Via Business Wire
News headline image
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites. 
Via Stocktwits
Topics Artificial Intelligence Government World Trade
News headline image
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
News headline image
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
News headline image
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗
Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen. 
Via Benzinga
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer ↗
The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose. 
Via Benzinga
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study ↗
AstraZeneca's Tagrisso with chemotherapy improved survival in advanced NSCLC, extending median overall survival by nearly 10 months over monotherapy. 
Via Benzinga
News headline image
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
News headline image
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July. 
Via The Motley Fool
News headline image
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.